iBio and AstralBio Forge AI Drug Discovery Alliance to Target Obesity and Cardiometabolic Diseases; Shares Skyrocket 226%
iBio, Inc. (NYSEA:IBIO), in partnership with AstralBio, Inc., has launched a collaboration to leverage artificial intelligence (AI) in the discovery and development of novel antibodies aimed at treating obesity and cardiometabolic diseases. This partnership combines iBio’s AI and machine learning capabilities alongside AstralBio’s experience in biologics and drug development to create treatments targeting specific health conditions.
“We are confident our AI-enabled technology is exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic space,” said iBio’s Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D. “The future of treating millions of patients affected by obesity and cardiometabolic disease globally will rely on next generation therapies aimed at enhancing both the efficacy and the tolerability profiles of current treatments.”
Highlights
iBio will employ its patented AI/Machine Learning platform to discover, engineer, and develop therapeutic targets focused on obesity, aiming to create a diverse and novel set of treatments for cardiometabolic diseases.
The collaboration is supported by a concurrent $15 million PIPE financing, extending iBio’s cash runway through the fiscal year 2025, indicating strong financial backing for the initiative.
iBio and AstralBio aim to rapidly develop a best-in-class portfolio for cardiometabolic disease treatment by combining their respective strengths in AI technology and biologics development.
The partnership has granted an exclusive license to iBio’s AI technology to identify and engineer four targets for cardiometabolic disease treatment, with an option for iBio to license additional targets from AstralBio.
The lead program of this collaboration focuses on targeting the transforming growth factor beta (TGFb) superfamily, with the aim of treating muscle wasting and obesity, showcasing the potential for innovative approaches to challenging medical conditions.
About iBio
iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for obesity, cardiometabolic, hard-to-target cancers, and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets.
